AdvanDx

AdvanDx, a subsidiary of OpGen Inc., is a company specializing in molecular diagnostics. It develops and markets advanced molecular diagnostic products designed for the diagnosis and treatment of life-threatening infections. The company's flagship products, such as the QuickFISH platform, are FDA-approved and CE-marked for the rapid identification of pathogens directly from blood cultures. These tests can deliver results in as little as 20 minutes, a significant reduction from traditional methods that can take days.

The primary clients for AdvanDx are healthcare providers, including hospitals and clinical laboratories, that require rapid and accurate diagnostic information to guide patient treatment, particularly in cases of suspected sepsis or other serious infections. The business model is centered on the sale of these diagnostic kits and associated instrumentation. By providing faster diagnostics, AdvanDx helps to improve patient outcomes, reduce healthcare costs, and combat the growing problem of antimicrobial resistance by enabling more targeted antibiotic therapy.

Keywords: molecular diagnostics, infectious diseases, rapid testing, antimicrobial resistance, blood culture, diagnostics, healthcare, life sciences, medical devices, pathogen identification